Home / Expertise / Life Sciences & Healthcare

Life Sciences & Healthcare

United Kingdom

Discovery, innovation, market awareness and understanding are key to those life sciences and healthcare entities providing services and finance towards, and developing therapies and services for, the improvement of patient outcomes.

Due to the highly regulated nature of the industry, as an operator, investor, adviser, developer or licensee, you will be dealing with complex legal and regulatory requirements to launch, maintain and deliver your products and services to the market.

Our Life Sciences team is immersed in the sector and we appreciate our clients' technology; we are not just lawyers, we are immunologists, geneticists, chemists and engineers. With this background we are ideally placed to really understand your business, how it is changing and what you want from a trusted advisor. Highly relevant to this sector is our fully integrated European patent attorney practice. Spanning multiple disciplines, both legal and scientific, our lawyers and patent attorneys operate as one team with a common outlook and objective for our clients - providing pragmatic, innovative and effective advice, efficiently.

Our Healthcare team is truly immersed in the sector with over 25 years of advising and shaping the sector through in depth experience, knowledge and sector associations and collaborations. We have significant experience of working within the public and private sectors, giving us a complete perspective of the issues you face, allowing us to offer you commercial and well rounded advice.

With active memberships in major industry bodies such as the ABPI, ABHI, BIVDA, EUCOMED / MedTech Europe, Healthcare UK and the BPF, we help shape the legal and compliance frameworks impacting the life sciences and healthcare sectors.

As well as clients' significant, complex and strategic transactional, financing and structuring matters, we regularly advise on day-to-day business operations, covering areas such as public procurement, tax, competition, IP protection, exploitation and enforcement, product liability, supply chain, outsourcing and other commercial agreements and employment and pensions matters, as well as regulatory, disputes, risk and compliance advice. Truly a full service.

Read more Read less

"Extensive pharmaceutical expertise with advice always provided in a business context. They understand our business and what we are trying to achieve with our IP strategy."

Legal 500, 2021

"CMS is one of the strongest city firms in this sector. They have real and deep rooted expertise. They deliver a Rolls-Royce service to some of the world’s most successful life sciences companies – many of whom they have deservedly achieved coveted “trusted adviser” status. They are one of the elite departments in this field. It is unsurprising that they have such a loyal client base."

Legal 500, 2021

"A one-stop-shop for us: its remarkable and successful mix of talent makes it stand out from the rest, and makes our lives much easier."

Chambers UK

Choose area


    Recent years have seen an increase in the numbers of biotech IPOs and more investment in the sector, however it can still be challenging accessing the finance necessary to fund R&D and to bring products to the market. As part of the biotech industry you will expect your lawyers to assist you in tackling these difficult financing and market challenges. Our team of sector specialists, including lawyers with technical backgrounds, understands the commercial drivers in this industry and can advise you on the full spectrum of legal matters.

    Read more

    Devices & Diagnostics

    In an increasingly competitive healthcare market, medical device and diagnostics companies need to ensure return on investment when developing innovative and reliable medical technologies and services. Devices and diagnostics are subject to complex regulatory and compliance frameworks and are often subject to competitive tendering so you will need lawyers who can reliably advise on pragmatic, compliant solutions.

    Read more


    With technology and digital innovation at the forefront of many advancements in the lifesciences industry and in healthcare delivery, organisations look  to consistently push boundaries to bring products and services to both the consumer and professional market. However, the regulation of ehealth solutions, devices and services is often outpaced by the novelty and innovation in the solutions themselves and at CMS, we understand the challenges this presents.

    Read more


    The healthcare sector in the UK and internationally continues to experience dynamic change underpinned by significant legal reforms. As an operator, investor, funder, developer or landlord in this sector, you are facing a highly regulated environment as well as significant public scrutiny.

    With increasing potential for the independent provision of health and social care along with an ageing population and technological advances, but with tightening public budgets, operating within the health and social care sectors presents both challenges and opportunities.

    Read more


    With ever increasing costs of gaining marketing authorisations for new drugs, fewer opportunities for blockbuster products and ongoing pressure on pricing, operating successfully in the pharmaceutical sector can be challenging. Our sector-focused team, many of whom have technical backgrounds, are able to help clients overcome these challenges and maximise the commercial opportunities.

    Read more
    equIP Life Sci­ences: from lab bench to busi­ness
    High­lights of our ex­per­i­ence in Life Sci­ences & Health­care in the UK
    Almir­all, S.A., on the trans­fer of its res­pir­at­ory fran­chise for an ini­tial con­sid­er­a­tion of USD 875m on com­ple­tion, and up to USD 1.22bn in de­vel­op­ment, launch and sales-re­lated mile­stone pay­ments.John­son...
    Law-Now: Lifes­ci­ences
    Vis­it Law-Now for leg­al know-how and com­ment­ary


    Show only
    2 September 2020
    Health­care M&A
    Get­ting the Deal Through – Health­care M&A ex­plores the main is­sues in health­care M&A trans­ac­tions. It also acts as a com­par­at­ive leg­al guide for cross bor­der or multi-jur­is­dic­tion­al activ­it­ies and a...
    14 December 2020
    CMS Ex­pert Guide to di­git­al health apps and telemedi­cine
    Fu­ture fa­cing Di­git­isa­tion is ad­van­cing stead­ily. Its pi­on­eer­ing in­nov­a­tions chal­lenge all parties in­volved. One of the most im­port­ant as­pects in this area is the huge po­ten­tial that lies in the di­git­isa­tion...
    13 January 2021
    EU­'s Por­tuguese pres­id­ency re­leases new draft of ePri­vacy Reg­u­la­tion
    On 5 Janu­ary 2021, the Coun­cil of the EU – with Por­tugal serving as the Pres­id­ent-in-Of­fice – re­leased a new draft ver­sion of the ePri­vacy Reg­u­la­tion, which is meant to re­place the ePri­vacy Dir­ect­ive...
    18 June 2020
    CMS ad­vises Bright­Cure on fun­drais­ing and ad­mis­sion to the In­dieBio Ac­cel­er­at­or
    In­ter­na­tion­al law firm CMS has ad­vised Bright­Cure, a start-up de­vel­op­ing pro­bi­ot­ic-based ther­apies for ur­in­ary tract in­fec­tions (UTIs), on its seed fun­drais­ing and ad­mis­sion to the In­dieBio Ac­cel­er­at­or...
    20 April 2020
    CMS Ex­pert Guide to ad­vert­ising of medi­cines and med­ic­al devices
    Ad­vert­ising of phar­ma­ceut­ic­als and med­ic­al devices is a chal­len­ging area for the Life Sci­ences and Health­care in­dustry.The leg­al frame­work is con­stantly chan­ging. Due to very few laws on this area, there...
    08 January 2021
    Un­ex­pec­ted scale-back of DAC6 tax re­port­ing
    HM­RC have an­nounced that the UK has scaled back the ap­plic­a­tion of the EU tax dis­clos­ure re­gime re­ferred to as “DAC6” so that only one out of the five EU “hall­marks” be­lieved to in­dic­ate tax avoid­ance...
    15 April 2020
    CMS wins four gongs at the 2019 CEE Leg­al Mat­ters Deal of the Year Awards
    CMS has been re­cog­nised as the win­ner in four cat­egor­ies at the 2019 CEE Leg­al Mat­ters Deal of the Year Awards. CMS was in­volved in 12 of the nom­in­ated deals and the firm has won for its work on lead­ing...
    20 April 2020
    CMS Ex­pert Guide to can­nabis law and le­gis­la­tion
    In re­cent years can­nabis trade and re­lated activ­ity has de­veloped in­to a growth busi­ness area. In the life sci­ences and health­care fields there have been in­creases in the num­bers of pa­tients hav­ing ac­cess...
    17 December 2020
    Trans­form­ing Pub­lic Pro­cure­ment – the Fi­nal Fron­ti­er?
    “For too long, mod­ern and in­nov­at­ive ap­proaches to pub­lic pro­cure­ment have been bogged down in bur­eau­crat­ic, pro­cess-driv­en pro­ced­ures. We need to aban­don these com­plic­ated and stifling rules and un­leash...
    9 April 2020
    Rene­go­ti­at­ing or can­cel­ling com­mer­cial ar­range­ments in light of COV­ID-19
    The spread of COV­ID-19 po­ten­tially un­der­mines the vi­ab­il­ity of a huge range of com­mer­cial ar­range­ments, from­con­tracts for one-off (or mul­tiple) events to long term sup­ply con­tracts. The reas­ons why these...
    16 December 2020
    EU Com­mis­sion pub­lishes pro­posed Data Gov­ernance Reg­u­la­tion
    On 25 Novem­ber 2020 the European Com­mis­sion pro­posed new rules on data gov­ernance – a pro­posed Data Gov­ernance Reg­u­la­tion, which is the first of a set of meas­ures an­nounced in the 2020 European strategy...
    13 January 2020
    High­lights of our ex­per­i­ence in Health­care
    Spire Health­care on a wide range of trans­ac­tions, in­clud­ing the dis­pos­al of two can­cer centres and the es­tab­lish­ment of a part­ner­ship with Gen­es­is Care. We also ad­vised on a cov­er­age dis­pute with its...